Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Probably the biggest objection to buying Lilly stock is its valuation. The big pharmaceutical company's shares trade at nearly 37.5 times forward earnings. Does this high multiple disqualify Lilly as ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...

Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.Most Read from Bloombe ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Eli Lilly stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its diabetes and weight-loss drugs.

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates. The disappointment led to a [15% plunge in Lilly’s shares]( ...

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that could shake up how the ...